FOLD
BASIC MATERIALSAmicus Therapeutics Inc
AI Insight
What's Moving FOLD Today?
No stock-specific AI insight has been generated for FOLD yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$4.5B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding314.0M
FOLD News
21 articles- Barclays holds 17.8M Amicus shares (NASDAQ: FOLD), 5.65% stakeStock Titan·May 15, 2026
- BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance RaisedYahoo Finance·May 5, 2026
- BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley SaysYahoo Finance·May 5, 2026
- BioMarin acquires Amicus Therapeutics for $4.8bnPharmaceutical-technology·Apr 28, 2026
- CIBRA Capital Buys Stake in Allied Gold StockMotley Fool·Apr 27, 2026
- BioMarin Completes Acquisition of Amicus TherapeuticsYahoo Finance·Apr 27, 2026
- CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)The Motley Fool·Apr 25, 2026
- Here is Why BioMarin (BMRN) is Projected to RallyYahoo Finance·Mar 31, 2026
- Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total ReturnYahoo Finance·Mar 29, 2026
- Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?Yahoo Finance·Mar 27, 2026
- Tarsus Pharmaceuticals Stock Earns Upgrade To RS RatingYahoo Finance·Mar 26, 2026
- Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Mar 26, 2026
- BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Mar 25, 2026
- Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF UpsideYahoo Finance·Mar 15, 2026
- Viking Therapeutics Stock Gets RS Rating UpgradeYahoo Finance·Mar 10, 2026
- Rice Hall James Loads Up on BIRK With 466,000 Shares BoughtMotley Fool·Mar 9, 2026
- Rice Hall James Buys QuidelOrtho StockMotley Fool·Mar 9, 2026
- Rice Hall James Buys Stride StockMotley Fool·Mar 9, 2026
- How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease PortfolioYahoo Finance·Mar 6, 2026
- Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor FocusYahoo Finance·Mar 5, 2026
- Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC FilingMotley Fool·Mar 3, 2026
All 21 articles loaded
Price Data
Open$0.00
Previous Close$14.46
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$4.5B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding314.0M
About Amicus Therapeutics Inc
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
BASIC MATERIALSPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—